Gilead Sciences Inc.

Robin Washington, age 46, is our Senior Vice President and Chief Financial Officer. Ms. Washington joined us in May 2008. Prior to joining us, Ms. Washington served as Chief Financial Officer of Hyperion Solutions, an enterprise software company that was acquired by Oracle Corporation in March 2007. Ms. Washington also spent nearly 10 years at PeopleSoft, a provider of enterprise application software, most recently in the role of Senior Vice President and Corporate Controller. She previously was a Director of Finance for Tandem Computers, an Accounting Analyst for the Federal Reserve Bank of Chicago and a Senior Auditor for Deloitte & Touche. Ms. Washington holds a bachelor s degree in business administration from the University of Michigan and an MBA from Pepperdine University. She currently serves on the board of directors of MIPS Technologies, Inc.

Dr. Bischofberger joined Gilead Sciences in 1990 and has served Executive Vice President for Research and Development since 2000 and Chief Scientific Officer since 2007. Prior to joining Gilead, Dr. Bischofberger was a Senior Scientist in Genentech?s DNA Synthesis Group from 1986 until 1990. Dr. Bischofberger received a PhD in organic chemistry from Zurich?s Eidgenossische Technische Hochschule and performed postdoctoral research in steroid chemistry at Syntex. He also performed additional research in organic chemistry and applied enzymology in Professor George Whiteside?s lab at Harvard University in Cambridge, Massachusetts.

Gregg H. Alton, age 43, is our Senior Vice President and General Counsel. Mr. Alton joined us in 1999, and was promoted to his current role in 2005. From 2001 until 2005, Mr. Alton served as our Vice President and General Counsel. From 1999 until 2001, Mr. Alton served as our Associate General Counsel. Prior to joining us, Mr. Alton was an attorney at the law firm of Cooley Godward Kronish LLP. In this role, Mr. Alton s practice focus was mergers and acquisitions, corporate partnerships and corporate finance transactions for healthcare and information technology companies. Mr. Alton is a member of the board and treasurer of the AIDS Healthcare Foundation, a member of the board of Oculus Innovative Sciences, Inc. and a member of the board of BayBio, a San Francisco Bay Area life sciences industry organization. He received his B.A. in Legal Studies from the University of California at Berkeley and his J.D. from Stanford Law School.

Dr. Cheng joined Gilead Sciences in 1999 and was appointed to his current role of Senior Vice President, Development Operations in February 2009. In this role, he is responsible for Gilead?s biometrics, clinical operations, drug safety and public health, project and portfolio management and regulatory affairs activities. Dr. Cheng previously served as Vice President, Clinical Research, overseeing Gilead?s clinical development activities for the company?s development-stage programs in HIV/AIDS. Prior to joining Gilead, Dr. Cheng trained in internal medicine at the University of California, Los Angeles. Dr. Cheng received his bachelor?s degree from the Johns Hopkins University and his medical degree and PhD in Cellular and Molecular Biology from Columbia University. He is board certified in internal medicine.

Mr. Caracciolo joined Gilead Sciences in 1997 and has served as Senior Vice President, Manufacturing since 2003 and Senior Vice President, Manufacturing and Operations since 2007. Prior to joining Gilead, Mr. Caracciolo spent six years as Vice President of Operations for Bausch & Lomb’s pharmaceutical division in Tampa, Florida and held various management positions at Sterling Drug, Inc. Mr. Caracciolo is a board member of the Keck Graduate Institute Advisory Council. Mr. Caracciolo received a bachelor’s degree in pharmaceutical science from St. John's University in New York State.

Paul Carter joined Gilead Sciences in 2006 and leads the company's commercial operations outside of North America. Prior to joining Gilead, Mr. Carter spent 14 years in various positions at GlaxoSmithKline (GSK), including as a General Manager in Europe and later as a Regional Head of international business in Asia. In this role he was a member of GSK's International Management Committee. Mr. Carter's experience also includes four years with Arthur Andersen's London practice. Mr. Carter is a fellow of the United Kingdom's Chartered Institute of Management Accountants. He holds a degree in Business Studies from Ealing School of Business and Management (now part of Thames Valley University).

Seigo Izumo, MD joined Gilead as Senior Vice President, Cardiovascular Therapeutics in September 2008. In this role, Dr. Izumo oversees Gilead?s growing cardiovascular business unit. Dr. Izumo most recently served as Vice President & Global Head of Cardiovascular Research at Novartis Institutes for BioMedical Research. Prior to joining Novartis in July 2003, he served as Professor of Medicine at Harvard Medical School in Boston and at Harvard-MIT Division of Health Sciences and Technology. In addition to his academic position at Harvard, Dr. Izumo was Director of Cardiovascular Research and Physician, Department of Medicine, Beth Israel Deaconess Medical Center, Boston and Director of the CardioGenomics Program, a National, Heart Lung and Blood Institute-sponsored initiative. Previously, he was Chief of the Cardiology Division and Professor of Internal Medicine and Biological Chemistry, University of Michigan Medical School in Ann Arbor. Dr. Izumo received his undergraduate and medical degrees from the University of Tokyo.

Ms. Little is a managing director and business development manager at WRF Capital. She concentrates primarily in the areas of healthcare and biotechnology and is responsible for identifying and developing start-up opportunities and investment decisions in new companies. Ms. Little is WRF Capital's investment manager for Therus, EKOS, Trace Detect, Point of CareWare, Amnis, Pacific Bioscience Laboratories, Second Act Partners, Corus Pharma (acquired by Gilead Sciences) and serves on the board of directors of Accium Biosciences. Previously, Ms. Little was manager of technology licensing and acquisitions and senior technology licensing manager. Before joining WRF, she worked as a marketing manager and market consultant. Ms. Little has a bachelor of arts in zoology from Pomona College and a master's in business administration from the University of Arizona.

Francis V. Chisari, M.D. is currently Professor and Head of the Division of Experimental Pathology at the Scripps Research Institute. Dr. Chisari received his M.D. from Cornell University Medical College in 1968. He has been on the Scripps faculty since 1975 and has published over 325 papers in the area of hepatitis virus immunobiology and pathogenesis. Dr. Chisari sits on several advisory boards including the Distinguished Advisory Committee at the UCSD Cancer Center, the Scientific Advisory Board for the Center for the Study of HCV at Rockefeller University, the International Research Scholars Program at the Howard Hughes Medical Institute and various expert panels sponsored by the NIAID. In recognition of his scientific contributions, Dr. Chisari has received many honors and awards including election to fellowship in the American Association for the Advancement of Science and the American Academy of Microbiology, and membership in the Association of American Physicians, the National Academy of Sciences, and the Institute of Medicine.

Dr. Baker is currently at Gilead Sciences, following Gilead's acquisition of Corus in 2006. He joined Corus Pharma as Vice President, Research in June 2002, with more than 20 years of research and drug discovery experience. Prior to joining Corus Pharma, Dr. Baker was Chief Operating Officer and VP Research for Optimer Pharmaceuticals, Inc., where he focused on developing novel therapeutics for infectious disease and cancer. Previously, Dr. Baker served as Senior Vice President of Research and Preclinical Development for PathoGenesis Corporation. Prior to PathoGenesis, Dr. Baker was Associate Research Fellow at Abbott Laboratories, where he directed research in cardiovascular and anti-infective drug discovery. While at Abbott his research developed the 11, 12 carbamate reaction sequence and full sugar analogs technology that enabled the ketolide class of macrolide antibiotics. Dr. Baker received his Ph.D. in organic chemistry from the University of Illinois, Champaign and his BS degree in chemistry from the University of Washington.